When a Patient Asks About Ibogaine

Consider an illustrative patient, a fictional composite. He is a veteran in his forties with posttraumatic stress disorder and a history of concussions. Two antidepressant trials and a course of trauma-focused therapy helped only partly. He takes sertraline and a low dose of quetiapine at night. He arrives with a news story about special operations veterans whose symptoms stayed better a year after ibogaine treatment abroad, and he wants to know whether he should book a clinic.

He is not asking whether ibogaine is approved. He knows it is not. He is asking whether the evidence is good enough, and whether it is safe enough, for someone like him. Two recent documents help with both parts of that question: an August follow-up of the veteran cohort and an October notice from the FDA. The FDA notice is more useful for his safety question than the headlines suggest.

On October 5, 2026, the FDA announced a request for information on the design of early-phase clinical trials of ibogaine drug products. The Federal Register notice followed on October 6, with comments due November 20, 2026. The notice says the Department of Health and Human Services is funding clinical development of ibogaine and expects the first federally supported trials to study adults with opioid use disorder and adults with PTSD.

The notice is explicit about its limits. It describes the agency's preliminary thinking, says it does not establish legally enforceable requirements, and states that nothing in it predetermines FDA action on any submission. It is a request for help designing safe studies. It is not an efficacy finding, an approval pathway with a date, or a statement that ibogaine works.

Its value for a clinician lies elsewhere. To describe how a trial might reduce risk, the FDA had to spell out the risks it is designing around.

The veteran cohort is a Stanford study of 30 male U.S. special operations veterans with predominantly mild traumatic brain injury. They had scheduled themselves for treatment at a clinic near Tijuana, Mexico, which gave oral ibogaine with intravenous magnesium; Stanford assessed them but did not administer the drug. The original report, published in Nature Medicine in January 2024, found large improvements in disability, PTSD, depression and anxiety at one month. The study had no control group, and the treatment came with coaching, group preparation and integration activities, and other wellness offerings. The authors wrote that the contribution of those non-ibogaine elements, travel, expectancy and other nonspecific effects could not be determined.

The follow-up, published in Translational Psychiatry on August 12, 2026, as an accepted manuscript, reports that 25 of the 30 participants completed 12-month assessments. Using mixed-effects models, the authors report sustained reductions in disability, PTSD, depression and anxiety through 12 months, with large effect sizes. Among participants who had the diagnosis at baseline and were in remission immediately after treatment, the estimated probability of remaining in remission at 12 months was 84% for PTSD, 66% for depression and 61% for anxiety. The starting remission groups contained 19, 11 and 11 people, respectively; the corresponding 95% confidence intervals were wide: 68-100%, 41-100% and 38-100%.

Two details change how those numbers should be read. First, the remission figures are conditional. They describe durability in small subgroups who had already remitted, not the share of all treated participants in remission at one year. They are censored survival estimates built from scheduled visits: participants lost to follow-up or without a recorded relapse were counted only through their last observation. There were 10 clinician-rated assessments at month 3, compared with 25 at month 12. Second, the abstract states that most participants used other psychedelics or pursued other interventions during follow-up. Stanford's summary of the paper reports that, over the following months, 23 participants took at least one psychedelic substance, most commonly 5-MeO-DMT, that 12 received therapy or counseling, and that three took psychotropic medications. The authors call the cohort naturalistic and say randomized trials are needed to separate ibogaine's effect from what followed. Four authors of the follow-up, including one of its two senior authors, are named inventors on Stanford-owned intellectual property related to magnesium-ibogaine.

This is a real signal, and it should not be waved away. A large, persistent change in a group with chronic symptoms, mostly of moderate severity, is the kind of observation that justifies careful trials. But persistence in an uncontrolled, self-selected cohort, most of whom went on to other psychedelic experiences, does not show how much of the change ibogaine caused. It also says little about people who do not resemble highly motivated special operations veterans able to travel for treatment, or who would not have passed the study's screening, which excluded people with psychotic disorders or judged to be at risk of suicidal behavior.

The Federal Register notice describes ibogaine as having serious cardiovascular risks and says it commonly causes substantial QTc prolongation, which has been associated with life-threatening ventricular arrhythmias and death. Ataxia is common, and the notice reports that in one study all participants experienced severe transient ataxia after a single 10 mg/kg dose. Whether ibogaine causes lasting neurologic or cognitive injury in humans, the notice says, has not been systematically studied.

The safeguards the notice sketches are demanding. Dosing should take place in an inpatient unit equipped to manage a life-threatening arrhythmia. Continuous cardiac monitoring should begin at dosing and end only when there are no abnormal rhythms and the QTc interval has returned near its pre-dose value, which the notice says could take as long as 36 hours. Elsewhere it gives examples of at least 36 hours in a telemetry unit and discharge only after criteria such as a 48-hour ECG without QTc prolongation, and it anticipates multi-day inpatient observation, noting that ibogaine and its active metabolite, noribogaine, are cleared slowly. Low potassium, calcium or magnesium should be corrected first. Participants could be genotyped for CYP2D6, the main enzyme converting ibogaine to noribogaine, with only fast and intermediate metabolizers included. An independent safety board would include a cardiologist, a neurologist, a psychiatrist and a biostatistician. Whether magnesium pretreatment reduces QTc prolongation is listed as a question to study, not an established protection.

The two published samples show why. The veteran study's authors concluded that ibogaine can be given safely to that population with magnesium, screening and medical monitoring. Three coauthors were shareholders in the treatment provider, Ambio Life Sciences, and inventors on a related provisional patent application. The study reported no serious or unexpected adverse events, no bradycardia and no clinically meaningful QT prolongation, defined as prolongation detectable on visual review of a continuous five-lead ECG over 12 to 16 hours; measured QTc values were not reported. Every participant had transient cerebellar signs, described as mild ataxia and intention tremor. In a Dutch open-label study, 14 patients with opioid use disorder received a single 10 mg/kg dose in a university psychiatry department, with ECGs every 30 minutes for the first 12 hours. Half reached a QTc above 500 ms, six still had a QTc above 450 ms more than 24 hours after dosing, seven developed mild bradycardia, and all had severe transient ataxia, unable to walk without support. No torsades de pointes was observed, though the authors note their ECG monitoring was not continuous. They concluded that ibogaine should not be used outside a well-controlled medical setting. Neither sample was large enough to estimate the risk of a rare fatal arrhythmia, and the different ways they measured QTc limit any comparison between them.

For a psychiatrist, the proposed eligibility criteria are the most telling part of the notice. Likely exclusions, it says, may include structural cardiovascular disease, a baseline QTcF of 430 ms or greater, abnormal heart rate or blood pressure, a personal or family history of arrhythmia or sudden cardiac death, a history of seizures, psychosis or bipolar disorder, recent suicidal thoughts or behavior, a neurodegenerative or balance disorder, significant liver or kidney impairment, and pregnancy or breastfeeding. Potential participants could be adults 18 to 55 who have stopped taking psychiatric medications. Before dosing, participants should stop drugs that prolong the QTc interval, slow the heart rate, interact with CYP2D6 or raise serotonin levels, a list the notice says includes antipsychotics and selective serotonin reuptake inhibitors such as paroxetine and sertraline.

These are proposals for research, not a clinical protocol, and they may change after comment. They describe the regulator's preliminary design considerations for studying a single supervised dose. The clinic in the veteran study also instructed participants to stop all psychiatric medications, along with CYP2D6 inhibitors, serotonergic drugs and several others, and screened with blood work and an ECG. Other treatment settings abroad may or may not do as much, and a patient is usually in a poor position to judge.

For the patient in the example, the draft criteria translate into specific questions. Sertraline and quetiapine are both in classes the notice would have trial participants stop. Stopping them is itself a clinical decision, with risks of withdrawal symptoms and the return of symptoms being treated. Withdrawal should be distinguished from relapse, and any worsening mood or new suicidal thinking would need to be assessed and monitored in him individually. He should not stop or change his medications on his own. The notice sets no washout period. If he asks for help coming off his medications so that he can travel, that request deserves a direct conversation, including the risk that he stops abruptly on his own if the answer is no. Recent suicidal thoughts, a family history of sudden cardiac death or a history of bipolar disorder would likely exclude him from the trials the FDA describes. A clinic that does not ask about his medications, his ECG, his family history or his mood and suicide history is telling him something about its standards, although a clinic that asks all of them has not thereby shown that it is safe.

The psychiatrist does not need to choose between dismissing his hope and endorsing his plan. A useful response separates four things he may be running together: what the veterans reported, what the study can establish about cause, what established treatments have not yet been tried or optimized, and what is still unknown about cardiac and neurologic safety. It also leaves room for what he is really asking for, which is usually relief from symptoms that have not responded well enough.

It is reasonable to tell him that the observed improvement is promising, that federally funded trials of ibogaine are now being designed, that the FDA's own design materials treat cardiac risk as serious enough to propose an inpatient unit able to manage a life-threatening arrhythmia, and that his current medications and history are among the factors those trials would screen for. If he still intends to travel, the conversation can turn to what he would want to know about the setting and to keeping him connected to care after he returns. Ibogaine remains unapproved and, in the United States, a Schedule I substance, so that support is different from supervising or arranging the treatment.

The evidence has moved from case reports and small observational studies toward planned trials. For now, the most concrete document a clinician can bring to the conversation is the FDA's list of what it thinks a study would need to reduce that risk, which is not proof that the risk can be made acceptable.

Source note: Sources were reviewed and rechecked prior to publication. The original veteran study and Dutch safety study were reviewed in full main text. The follow-up's accepted manuscript and supplement were checked for remission definitions, starting groups, uncertainty and assessment counts. Subsequent-treatment counts remain attributed to Stanford, with a denominator discrepancy in the follow-up reports recorded in the evidence audit. NICE guidance and quetiapine labeling support the general withdrawal discussion, not an individual risk estimate. This article gives no dosing, medication-discontinuation or monitoring protocol and does not endorse or arrange ibogaine treatment. The patient is a fictional composite.

Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Appropriate assessment and treatment depend on the individual, setting, and current authoritative guidance. Patients should coordinate treatment decisions with their treating clinicians.